Select Language
CD3 delta
CD3 delta Overview
| English Name | T cell surface glycoprotein CD3 | Approved Drugs | 10 |
| Drugs in Clinical Trials | 198 | Target Synonym | CD3 Complex |
| Highest Development Stage | Approved | ||
| English Name | T cell surface glycoprotein CD3 |
| Target Synonym | CD3 Complex |
| Approved Drugs | 10 |
| Drugs in Clinical Trials | 198 |
| Highest Development Stage | Approved |
CD3 delta Product List
- Product Category
Protein (3)
- Product Status
Launched (3)
- Species
Human (2)Cynomolgus (1)
- Tag
His Tag (2)His Tag & Avi Tag (1)
- Conjugate
Unconjugated (2)Biotin-labeled (1)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|---|
CDD-H5224 |  Human | HEK293 | Human CD3 delta Protein, His Tag, low endotoxin |  |  | |
CDD-H82E3 | Human | HEK293 | Biotinylated Human CD3 delta Protein, His,Avitag™ |  | | |
CDD-C52H8 |  Cynomolgus | HEK293 | Cynomolgus CD3 delta Protein, His Tag |  | |
Total: 3
- 1
CD3 delta Background
T-cell surface glycoprotein CD3 delta, also known as CD3D. CD3D, together with CD3- epsilon(CD3E) , CD3-gamma and CD3-zeta, and the T-cell receptor alpha/beta and gamma/delta heterodimers, forms the T cell receptor-CD3 complex. T cell receptor-CD3 complex plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways.When antigen presenting cells (APCs) activate T-cell receptor (TCR), TCR-mediated signals are transmitted across the cell membrane by the CD3 chains CD3D, CD3E, CD3G and CD3Z.
CD3 delta Synonyms
CD3D,CD3-DELTA,T3D
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Recombinant Anti-EpCAM and Anti-CD3Human-mouse Chimeric Bispecific Antibody for Injection (Wuhan Yzy Biopharma Co Ltd) | M-701 | Phase 3 Clinical | Wuhan Yzy Biopharma Co Ltd | Ascites; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Hydrothorax; Neoplasms; Ovarian Neoplasms; Pleural Effusion, Malignant; Solid tumours; Stomach Neoplasms | Details |
| Etentamig | TNB-383B; ABBV-383 | Phase 3 Clinical | TeneoOne Inc | Immunoglobulin Light-chain Amyloidosis; Multiple Myeloma; Waldenstrom Macroglobulinemia | Details |
| Brenetafusp | IMC-F106C; PRAME HLA-A02 | Phase 3 Clinical | Immunocore Ltd | Melanoma; Solid tumours | Details |
| Xaluritamig | AMG-509 | Phase 3 Clinical | Amgen Inc, Xencor Inc | Castration-Sensitive Prostate Neoplasms; Hormone-Sensitive Prostate Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Sarcoma, Ewing | Details |
| QLS-32015 | QLS-32015; QLS32015 | Phase 3 Clinical | Qilu Pharmaceutical Co Ltd | Multiple Myeloma | Details |
| Obrixtamig | BI-764532; OBT620 | Phase 3 Clinical | C.H. Boehringer Sohn Ag & Co. Kg | Carcinoma, Neuroendocrine; Glioma; Neoplasms; Neuroendocrine Tumors; Small Cell Lung Carcinoma | Details |
| Ramantamig | JNJ-79635322; JNJ-5322 | Phase 3 Clinical | Janssen Research & Development Llc | Multiple Myeloma | Details |
| Velinotamig | GR-1803 | Phase 3 Clinical | Chongqing Genrix Biopharmaceutical Co Ltd, Genrix (Shanghai) Biopharmaceutical Co Ltd | Autoimmune Diseases; Lupus Erythematosus, Systemic; Multiple Myeloma | Details |
| Gamgertamig | CM-336; OM336 | Phase 3 Clinical | Keymed Biosciences Co Ltd | Amyloidosis; Anemia, Hemolytic, Autoimmune; Cytopenia; Evans syndrome; Immunoglobulin Light-chain Amyloidosis; Multiple Myeloma; Myositis; Purpura, Thrombocytopenic, Idiopathic; Sjogren's Syndrome; Skin Diseases, Vesiculobullous | Details |
| Pasritamig | JNJ-8343; JNJ-78278343 | Phase 3 Clinical | Janssen Research & Development Llc, Zymeworks Inc | Hormone-Sensitive Prostate Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details |
| TQB-2825 | TQB-2825 | Phase 3 Clinical | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | Hematologic Neoplasms; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell | Details |
| QLS-31905 | QLS-31905 | Phase 3 Clinical | Qilu Pharmaceutical Co Ltd | Bile Duct Neoplasms; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| Surovatamig | TNB-486; AZD-0486; AZD0486 | Phase 3 Clinical | Teneobio Inc | Arthritis, Rheumatoid; Large B Cell Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Lupus Erythematosus, Systemic; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Neoplasms; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
| Alveltamig | ZG-006; ZG006 | Phase 3 Clinical | Gensun Biopharma Inc, Suzhou Zelgen Biopharmaceuticals Co Ltd | Carcinoma, Neuroendocrine; Neoplasms; Prostatic Neoplasms; Small Cell Lung Carcinoma; Solid tumours | Details |
| Anti-CD3/humanized 3F8 bispecific antibody-activated T lymphocytes (University of Virginia) | Phase 2 Clinical | University Of Virginia | Neuroblastoma | Details | |
| GNR-084 | GNR-084 | Phase 2 Clinical | Generium Pharmaceuticals, Iontas | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
| Anti-CD3 and anti-HER2 BiTE-expressing T cell (MedImmune) | Phase 2 Clinical | Huazhong University Of Science And Technology, Medimmune, University Of Michigan, University Of Virginia Cancer Center | Breast Neoplasms | Details | |
| Vibecotamab | XmAb-14045 | Phase 2 Clinical | Xencor Inc | Blastic Plasmacytoid Dendritic Cell Neoplasm; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details |
| α/β CD3+/CD19+ cell depleted stem cell therapy (New York Medical College) | Phase 2 Clinical | New York Medical College | Anemia; Anemia, Aplastic; Anemia, Sickle Cell; Hodgkin Disease; Kostmann Syndrome; Leukemia; Lymphoma, Non-Hodgkin; Thalassemia; Thrombocytopenia | Details | |
| Gocatamig | HPN-328; MK-6070; DS-3280 | Phase 2 Clinical | Harpoon Therapeutics | Carcinoma, Neuroendocrine; Small Cell Lung Carcinoma | Details |
| Cibisatamab | RG-7802; RO-6958688; CEA-CD3 TCB; CEA-TCB | Phase 2 Clinical | F. Hoffmann-La Roche Ltd | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Solid tumours | Details |
| CD3/CD19 neg allogeneic BMT (National Institute of Allergy and Infectious Diseases/University of Pittsburgh) | Phase 2 Clinical | National Institute Of Allergy And Infectious Diseases (Niaid), University Of Pittsburgh | Female Urogenital Diseases; Inflammation; Primary Immunodeficiency Diseases | Details | |
| MDX-2003 | MDX-2003 | Phase 2 Clinical | ModeX Therapeutics Inc | Autoimmune Diseases; Leukemia, B-Cell; Lymphoma; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Primary mediastinal B cell lymphoma; Waldenstrom Macroglobulinemia | Details |
| JS-203 | JS-203 | Phase 2 Clinical | Shanghai Junshi Biological Engineering Co Ltd | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details |
| MBS-303 | MBS-303; MSC-303; MSB-303 | Phase 2 Clinical | Beijing Mabworks Biotech Co Ltd | Glomerulonephritis; Lupus Nephritis; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Nephrotic Syndrome | Details |
| JY-016 | JY-016 | Phase 2 Clinical | Beijing Eastern Biotech Co Ltd, Beijing Jingyitaixiang Technology Development Co Ltd | Colorectal Neoplasms; Lung Neoplasms; Solid tumours | Details |
| HBM-7022 | HBM-7022; AZD-5863 | Phase 2 Clinical | Harbour Biomed | Carcinoma, Pancreatic Ductal; Esophageal adenocarcinoma; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Neoplasms; Pancreatic Neoplasms; Stomach Neoplasms | Details |
| EMB-07 | EMB-07 | Phase 2 Clinical | Shanghai Epimab Biotherapeutics, Inc | Adenocarcinoma of Lung; Colorectal Neoplasms; Lymphoma; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Uterine Neoplasms | Details |
| GB-261 | CND261; CND-261; GB-261 | Phase 2 Clinical | Genor Biopharma Co Ltd | Arthritis, Rheumatoid; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Scleroderma, Systemic | Details |
| HER2 FPBMC therapy (University Of Virginia) | HER2 FPBMC | Phase 2 Clinical | University Of Virginia | Breast Neoplasms; Prostatic Neoplasms | Details |
| Anti-CD3 × Anti-EGFR Bispecific-armed T Cells (EGFR BATs) therapy | Phase 2 Clinical | University Of Virginia | Glioblastoma; Pancreatic Neoplasms | Details | |
| REGN-7041 | REGN7041; REGN-7041 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Uveitis | Details |
| GPRC5D/CD3 BiTEs | GPRC5D/CD3 BiTEs | Phase 2 Clinical | Institute Of Hematology & Blood Diseases Hospital | Multiple Myeloma | Details |
| ZGGS-34 | ZGGS34; ZGGS-34 | Phase 2 Clinical | Suzhou Zelgen Biopharmaceuticals Co Ltd | Solid tumours | Details |
| HY-05350 | HY-0005; HY-05350 | Phase 2 Clinical | Sichuan Huiyu Seacross Pharma Technology Ltd | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Mesothelioma; Ovarian Neoplasms; Pancreatic Neoplasms; Solid tumours | Details |
| Vonsetamig | REGN-5459 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Lupus Nephritis; Multiple Myeloma; Renal Insufficiency, Chronic | Details |
| NVG-222 | NVG-222 | Phase 2 Clinical | NovalGen Ltd | Hematologic Neoplasms; Neoplasms | Details |
| VNX-101 | VNX-101 | Phase 2 Clinical | Vironexis Biotherapeutics Inc | Burkitt Lymphoma; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Primary mediastinal B cell lymphoma | Details |
| BCD-248 | BCD-248 | Phase 2 Clinical | BIOCAD JSC | Multiple Myeloma | Details |
| Anti-CD3 x Anti-EGFR Bispecific Antibody (EGFRBi) Armed Fresh Peripheral Blood Mononuclear Cells therapy(University Of Virginia) | Phase 2 Clinical | University Of Virginia | Pancreatic Neoplasms | Details | |
| CD3-CD20 Bisspecific Antibody Based Therapy Combined With CD19-CAR T Cells therapy(Institute Of Hematology & Blood Diseases Hospital) | Phase 2 Clinical | Institute Of Hematology & Blood Diseases Hospital | Lymphoma, B-Cell | Details | |
| SHR-7787 | SHR-7787; SHR7787 | Phase 2 Clinical | Shanghai Hengrui Pharmaceutical Co Ltd | Small Cell Lung Carcinoma; Solid tumours | Details |
| MDX-2001 | MDX2001; MDX-2001 | Phase 2 Clinical | ModeX Therapeutics Inc | Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Rectal Neoplasms; Stomach Neoplasms; Thyroid Neoplasms; Uterine Cervical Neoplasms | Details |
| SCTB-35 | SCTB35; SCTB-35 | Phase 2 Clinical | SinoCelltech Ltd | Autoimmune Diseases; Lupus Erythematosus, Systemic; Lymphoma, B-Cell | Details |
| IBI-3003 | IBI3003; IBI-3003 | Phase 2 Clinical | Multiple Myeloma | Details | |
| MBS-314 | MBS-314 | Phase 2 Clinical | Beijing Mabworks Biotech Co Ltd | Multiple Myeloma | Details |
| IMC-R117C | IMC-R-117-C | Phase 2 Clinical | Immunocore Holdings PLC | Colorectal Neoplasms; Neoplasms; Pancreatic Neoplasms; Stomach Neoplasms | Details |
| MP0533 | MP0533 | Phase 2 Clinical | Molecular Partners Ag | Leukemia, Myeloid, Acute | Details |
| TQB-2934 | TQB2934; TQB-2934 | Phase 2 Clinical | Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group | Amyloidosis; Immunoglobulin Light-chain Amyloidosis; Multiple Myeloma; Neoplasms, Plasma Cell | Details |
| Mipletamig | APVO-436; APVO436 | Phase 2 Clinical | Aptevo | Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | Details |
| Emfizatamab | GNC-038 | Phase 2 Clinical | Sichuan Baili Pharmaceutical Co Ltd, SystImmune | Arthritis, Rheumatoid; Central Nervous System Lymphoma; Lupus Erythematosus, Systemic; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Solid tumours | Details |
| CMD-011 | CMD-011 | Phase 2 Clinical | Zhejiang Shimai Pharmaceutical Co Ltd | Carcinoma, Hepatocellular; Liver Neoplasms | Details |
| YK-012 | YK012 | Phase 2 Clinical | Excyte Biopharma Ltd | Glomerulonephritis, Membranous; Kidney Diseases; Lupus Erythematosus, Systemic; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Nephrosis; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details |
| GEN-1047 | GEN-1047 | Phase 2 Clinical | Genmab A/S | Endometrial Neoplasms | Details |
| Olsutamig | REGN-4336 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Prostatic Neoplasms, Castration-Resistant | Details |
| CM-350 | CM-350 | Phase 2 Clinical | Keymed Biosciences Co Ltd | Solid tumours | Details |
| LBL-034 | LBL-034 | Phase 2 Clinical | Nanjing Leadsbiolabs Co Ltd | Multiple Myeloma; Neoplasms | Details |
| LBL-033 | LBL-033 | Phase 2 Clinical | Nanjing Leadsbiolabs Co Ltd | Neoplasms | Details |
| F-182112 | F182112; F-182112 | Phase 2 Clinical | Shandong New Time Pharmaceutical Co Ltd | Lupus Erythematosus, Systemic; Multiple Myeloma | Details |
| ICP-B02 | CM-355; ICP-B02 | Phase 2 Clinical | Beijing Tiannuo Jiancheng Pharmaceutical Technology Co Ltd, Keymed Biosciences Co Ltd | Hematologic Neoplasms; Hematoma; Lymphoma; Lymphoma, Non-Hodgkin | Details |
| SMET-12 | SMET-12 | Phase 2 Clinical | Zhejiang Shimai Pharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung; Solid tumours | Details |
| Nebratamig | GNC-035 | Phase 2 Clinical | Sichuan Baili Pharmaceutical Co Ltd | Breast Neoplasms; Hematologic Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Metastatic breast cancer; Solid tumours | Details |
| Recombinant humanized anti-BCMA/CD3 bispecific antibody(New Time Pharmaceutical) | Phase 2 Clinical | Shandong New Time Pharmaceutical Co Ltd | Lupus Erythematosus, Systemic; Multiple Myeloma | Details | |
| CN-201 | CN-201; MK-1045 | Phase 2 Clinical | Curon Biopharmaceutical Ltd | Arthritis, Rheumatoid; Leukemia, B-Cell; Lupus Erythematosus, Systemic; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
| EX-103 | EX-103; EX103 | Phase 2 Clinical | Guangzhou Excelmab Inc | Arthritis, Rheumatoid; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin | Details |
| Anti-CD3 monoclonal antibody (Jinan Tiankang Biological Products) | Phase 2 Clinical | Jinan Tiankang Biological Products Co Ltd | Anemia, Aplastic | Details | |
| Cevostamab | RG-6160; BFCR-4350A; RO-7187797 | Phase 2 Clinical | Genentech Inc | Lupus Erythematosus, Systemic; Multiple Myeloma | Details |
| Anti-CD3/anti-EGFR -activated T cells (Barbara Ann Karmanos Cancer Institute) | Phase 2 Clinical | Barbara Ann Karmanos Cancer Institute, University Of Virginia | Pancreatic Neoplasms | Details | |
| Ubamatamab | REGN-4018 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Fallopian Tube Neoplasms; Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms | Details |
| Anti-CD3-anti-HER2-activated T cells | Phase 2 Clinical | Transtarget | Bone metastases; Breast Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details | |
| A-319 | A-319 | Phase 1 Clinical | Evive Biotech Ltd | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Arthritis, Rheumatoid; Leukemia, B-Cell; Lupus Erythematosus, Systemic; Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details |
| Podentamig | HPN-217; BCMA TriTAC | Phase 1 Clinical | Abbvie Inc, Harpoon Therapeutics | Multiple Myeloma | Details |
| Membrane bound ligand T-SIGn virus | NG-348 | Phase 1 Clinical | Akamis Bio Ltd | Neoplasms | Details |
| Flotetuzumab | S-80880; MGD-006; RES-234 | Phase 1 Clinical | Macrogenics Inc | Blastic Plasmacytoid Dendritic Cell Neoplasm; Hematologic Neoplasms; Hodgkin Disease; Leukemia; Leukemia, Biphenotypic, Acute; Leukemia, Hairy Cell; Leukemia, Myelogenous, Chronic; Leukemia, Myeloid, Acute; Mastocytosis, Systemic; Neoplasms, Plasma Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Details |
| NG-641 | EnAd-FAP-BiTE; EnAd-FAP-Tac; NG-641; NG-aFAP | Phase 1 Clinical | Akamis Bio Ltd | Neoplasm Metastasis; Neoplasms, Glandular and Epithelial; Squamous Cell Carcinoma of Head and Neck | Details |
| MGD-014 | MGD-014 | Phase 1 Clinical | Macrogenics Inc | HIV Infections | Details |
| JNJ-63898081 | JNJ-63898081; JNJ-8081 | Phase 1 Clinical | Johnson & Johnson Innovative Medicine | Neoplasms | Details |
| K-193 | K-193 | Phase 1 Clinical | Beijing Lvzhu Biological Technology Co Ltd | Lymphoma, B-Cell | Details |
| Anti-EGFR-bispecific antibody armed activated T-cell therapy (Memorial Sloan Kettering Cancer Center) | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center | Pancreatic Neoplasms | Details | |
| Runimotamab | RO-7227780; BTRC-4017A; RG-6194 | Phase 1 Clinical | Genentech Inc | Solid tumours | Details |
| Autologous T-cell therapy (anti-PSMA-CD3), Roger Williams Medical Center | Phase 1 Clinical | Roger Williams Medical Center | Prostatic Neoplasms | Details | |
| Besufetamig | ONO-4685 | Phase 1 Clinical | Merus Nv | Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, T-Cell; Plaque psoriasis | Details |
| M-802(Wuhan Yzy Biopharma/CSPC Pharmaceutical) | M-802 | Phase 1 Clinical | CSPC Pharmaceutical Group Ltd, Wuhan Yzy Biopharma Co Ltd | Breast Neoplasms; Ovarian Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| Emirodatamab | AMG-427 | Phase 1 Clinical | Amgen Inc | Leukemia, Myeloid, Acute | Details |
| SAR-442257 | SAR-442257 | Phase 1 Clinical | Sanofi | Neoplasms | Details |
| CC-1 | CC-1 | Phase 1 Clinical | BiconY Therapeutics Gmbh | Prostatic Neoplasms | Details |
| Acapatamab | AMG-160 | Phase 1 Clinical | Amgen Inc | Carcinoma, Non-Small-Cell Lung; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details |
| Alnuctamab | EM-901; BMS-986349; CC-93269 | Phase 1 Clinical | Engmab Ag | Lupus Erythematosus, Systemic; Multiple Myeloma | Details |
| Pavurutamab | AMG-701 | Phase 1 Clinical | Amgen Inc | Multiple Myeloma | Details |
| EX-101 (Excelmab) | Phase 1 Clinical | ExcelMab Inc | Breast Neoplasms; Solid tumours; Stomach Neoplasms | Details | |
| HPN-536 | HPN-536 | Phase 1 Clinical | Harpoon Therapeutics | Neoplasms | Details |
| CC-3 | CC-3 | Phase 1 Clinical | Eberhard Karls University Of Tubingen, Germany | Breast Neoplasms; Colorectal Neoplasms; Gastrointestinal Neoplasms; Penile Neoplasms; Sarcoma | Details |
| MGD-020 | MGD020 | Phase 1 Clinical | Macrogenics Inc | HIV Infections | Details |
| BC-004 | BC-004 | Phase 1 Clinical | Shandong Buchang Pharmaceuticals Co Ltd | Breast Neoplasms; Solid tumours | Details |
| EX-105 | EX-105; EX105 | Phase 1 Clinical | Guangzhou Excelmab Inc | Solid tumours | Details |
| BA-3182 | BA-3182 | Phase 1 Clinical | Bioatla | Adenocarcinoma; Solid tumours | Details |
| BA-1202 | BA-1202 | Phase 1 Clinical | Shandong Boan Biotechnology Co Ltd | Solid tumours | Details |
| CLN-978 | CLN-978; NexGem | Phase 1 Clinical | Adimab LLC | Arthritis, Rheumatoid; Lupus Erythematosus, Systemic; Lymphoma, Non-Hodgkin; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Sjogren's Syndrome | Details |
| MGD-024 | MGD-024 | Phase 1 Clinical | Macrogenics Inc | Blastic Plasmacytoid Dendritic Cell Neoplasm; Hodgkin Disease; Leukemia, B-Cell; Leukemia, Hairy Cell; Leukemia, Myelogenous, Chronic; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Neoplasms | Details |
| Cabotamig | ARB-202 | Phase 1 Clinical | Arbele Corp | Biliary Tract Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal adenocarcinoma; Gastrointestinal Neoplasms; Liver Neoplasms; Neuroendocrine Tumors; Pancreatic Neoplasms; Stomach Neoplasms | Details |
| CLN-049 | CLN-049 | Phase 1 Clinical | Eberhard-Karls Universitaet Tuebingen, German Cancer Research Center (Dkfz) | Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | Details |
| XmAb-819 | XmAb-819 | Phase 1 Clinical | Xencor Inc | Carcinoma, Renal Cell; Kidney Neoplasms | Details |
| NILK-2301 | NI-2301; NILK-2301 | Phase 1 Clinical | Novimmune Sa | Colorectal Neoplasms; Solid tumours | Details |
| SAR-446309 | AMX-818; HER2-XPAT; SAR-446309; VIR-5818 | Phase 1 Clinical | Amunix Pharmaceuticals Inc | Neoplasms; Solid tumours | Details |
| JNJ-95566692 | JNJ-95566692 | Phase 1 Clinical | Janssen Research & Development Llc | Lymphoma, Non-Hodgkin | Details |
| CD33Bi FPBMC (University Of Virginia) | Phase 1 Clinical | University Of Virginia | Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Myelodysplastic-Myeloproliferative Diseases | Details | |
| VSV-02 | VSV-02 | Phase 1 Clinical | Joint Biosciences Ltd | Breast Neoplasms; Lung Neoplasms; Melanoma; Neoplasms; Solid tumours | Details |
| KT-501 | KT501; KT-501 | Phase 1 Clinical | Kali Therapeutics Inc | Arthritis, Rheumatoid | Details |
| INCA-035784 | INCA-035784; INCA035784 | Phase 1 Clinical | Incyte Corp | Myeloproliferative Disorders | Details |
| HLX-3901 | HLX-3901 | Phase 1 Clinical | Shanghai Henlius Biotech Inc | Carcinoma, Neuroendocrine; Neoplasm Metastasis; Small Cell Lung Carcinoma; Solid tumours | Details |
| BiTE-EV Therapy(Beijing GoBroad Hospital) | Phase 1 Clinical | Beijing GoBroad Hospital | Leukemia | Details | |
| BGB-B455 | BGB-B455 | Phase 1 Clinical | BeOne Medicines Ltd | Solid tumours | Details |
| SSS-59 | SSS59; SSS-59 | Phase 1 Clinical | Shenyang Sunshine Pharmaceutical Co Ltd | Neoplasms | Details |
| ABO-2203 | ABO2203; ABO-2203 | Phase 1 Clinical | Abogen Biosciences Co Ltd | Lymphoma, B-Cell | Details |
| LY-4152199 | LY-4152199; LY4152199 | Phase 1 Clinical | Eli Lilly And Company | Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin | Details |
| JNJ-70218902 | JNJ-70218902 | Phase 1 Clinical | Johnson & Johnson Innovative Medicine | Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Myelodysplastic Syndromes; Neoplasms; Prostatic Neoplasms, Castration-Resistant; Solid tumours | Details |
| ARC-101 | ARC101; ARC-101 | Phase 1 Clinical | Third Arc Bio Inc | Endometrial Neoplasms; Lung Neoplasms; Ovarian Neoplasms; Solid tumours | Details |
| DS-2243 | DS-2243a; DS-2243 | Phase 1 Clinical | Daiichi Sankyo Co Ltd | Sarcoma; Solid tumours | Details |
| CLSP-1025 | CLSP-1025 | Phase 1 Clinical | Clasp Therapeutics Inc | Breast Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Urinary Bladder Neoplasms | Details |
| ZHB-015 | ZHB-015; ZHB015; ZHB-C003 | Phase 1 Clinical | Zonhon Biopharma Institute Inc | Solid tumours | Details |
| NPX-372 | NPX372; NPX-372 | Phase 1 Clinical | NextPoint Therapeutics Inc | Solid tumours | Details |
| APTN-101 | CBRX-101; APTN 101 | Phase 1 Clinical | Adaptin Bio Inc | Glioblastoma; Glioma | Details |
| TQB-2029 | TQB2029; TQB-2029 | Phase 1 Clinical | Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group | Multiple Myeloma | Details |
| SAR-446368 | SAR446368; SAR-446368; VIR-5525; AMX-525 | Phase 1 Clinical | Amunix Pharmaceuticals Inc | Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details |
| GS-8588 | GS-8588 | Phase 1 Clinical | Gilead Sciences Inc | HIV Infections | Details |
| GNC-077 | GNC-077; GNC077 | Phase 1 Clinical | Baili-Bio (Chengdu) Pharmaceutical Co Ltd, Sichuan Baili Pharmaceutical Co Ltd | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms; Metastatic breast cancer; Solid tumours | Details |
| Mesothelin x CD3 Bispecific Antibody(Integral Molecular) | CT-95; LNK101; LNK-101 | Phase 1 Clinical | Integral Molecular Inc | Carcinoma, Ovarian Epithelial; Cholangiocarcinoma; Colorectal Neoplasms; Mesothelioma; Neoplasm Metastasis; Neoplasms; Pancreatic Neoplasms; Solid tumours | Details |
| CM-380 | CM380; CM-380 | Phase 1 Clinical | Keymed Biosciences Co Ltd | Multiple Myeloma | Details |
| CMDE-005 | CMDE005; CMDE-005; CMD-E005 | Phase 1 Clinical | Zhejiang Shimai Pharmaceutical Co Ltd | Solid tumours | Details |
| QL-335 | QL-335; QL335 | Phase 1 Clinical | Qlsf Biotherapeutics Inc | Colorectal Neoplasms | Details |
| LNF-2007 | LNF-2007; LNF2007 | Phase 1 Clinical | Shandong New Time Pharmaceutical Co Ltd | Solid tumours | Details |
| QL-325 | QL-325 | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd, Qlsf Biotherapeutics Inc | Leukemia, Myeloid, Acute | Details |
| JNJ-67571244 | JNJ-1244; JNJ-67571244; JNJ-67371244 | Phase 1 Clinical | Johnson & Johnson | Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | Details |
| QLS-4131 | QLS-4131; QLS4131 | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | Lupus Erythematosus, Systemic; Multiple Myeloma | Details |
| CTIM-76 | CTIM-76 | Phase 1 Clinical | Integral Molecular Inc | Endometrial Neoplasms; Neoplasms; Ovarian Neoplasms; Solid tumours; Testicular Neoplasms | Details |
| YKST-02 | YKST02; YKST-02 | Phase 1 Clinical | Excyte Biopharma Ltd | Multiple Myeloma | Details |
| JNJ-79032421 | JNJ-79032421; JNJ-2421 | Phase 1 Clinical | Janssen Research & Development Llc | Solid tumours | Details |
| JNJ-87890387 | JNJ-87890387 | Phase 1 Clinical | Janssen Research & Development Llc | Neoplasms; Solid tumours | Details |
| AMX-500 | VIR-5500; SAR-446329; SAR446329; AMX-500 | Phase 1 Clinical | Amunix Pharmaceuticals Inc | Prostatic Neoplasms, Castration-Resistant | Details |
| XmAb-541 | XmAb541; XmAb-541 | Phase 1 Clinical | Xencor Inc | Endometrial Neoplasms; Germinoma; Neoplasms, Germ Cell and Embryonal; Ovarian germ cell tumor; Ovarian Neoplasms | Details |
| [89Zr]Zr-BI-764532 | Phase 1 Clinical | Boehringer Ingelheim International Gmbh, C.H. Boehringer Sohn Ag & Co. Kg | Carcinoma, Neuroendocrine; Small Cell Lung Carcinoma | Details | |
| TGI-6 | TGI-6 | Phase 1 Clinical | Hefei TG ImmunoPharma Co Ltd | Colorectal Neoplasms; Solid tumours | Details |
| SIM-0500 | SIM-0500; SIM0500 | Phase 1 Clinical | Simcere Pharmaceutical Group Ltd | Bone Marrow Neoplasms; Multiple Myeloma | Details |
| Recombinant anti BCMA/CD3 bispecific antibody(Hualan Genetic Engineering) | Phase 1 Clinical | Hualan Genetic Engineering (Henan) Co Ltd | Multiple Myeloma | Details | |
| AMG 305 | AMG 305; AMG-305 | Phase 1 Clinical | Amgen Inc | Solid tumours | Details |
| Oncolytic Virus R130（Yunying Medical） | R130; R-130; R-130-OV | Phase 1 Clinical | Shanghai Yunying Medical Technology Co Ltd | Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Bronchogenic; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Neoplasms; Fallopian Tube Neoplasms; Gastrointestinal Neoplasms; Genital Neoplasms, Female; Head and Neck Neoplasms; Kidney Neoplasms; Laryngeal Neoplasms; Liver Neoplasms; Lung Neoplasms; Melanoma; Nose Neoplasms; Osteosarcoma; Otorhinolaryngologic Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms; Pharyngeal Neoplasms; Sarcoma; Small Cell Lung Carcinoma; Solid tumours; Stomach Neoplasms | Details |
| SAIL-66 | SAIL66; SAIL-66 | Phase 1 Clinical | Chugai Pharmaceutical Co Ltd | Solid tumours | Details |
| IMC-P115C | IMC-P-115-C; PRAME-HLE-A02 | Phase 1 Clinical | Immunocore Holdings PLC | Carcinoma, Adenoid Cystic; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Endometrial Neoplasms; Melanoma; Neoplasms; Ovarian Neoplasms; Sarcoma, Endometrial Stromal; Sarcoma, Synovial; Small Cell Lung Carcinoma; Solid tumours; Uterine Neoplasms | Details |
| RG-6524 | RO-7616789; ALPS-12; RG6524 | Phase 1 Clinical | F. Hoffmann-La Roche Ag | Carcinoma, Neuroendocrine; Small Cell Lung Carcinoma | Details |
| BR-115 | CMG-6-A-19; CMG6A19; BR115; BR-115 | Phase 1 Clinical | Chengdu Chimagen Biosciences Co Ltd | Solid tumours | Details |
| OBT620 | OBT620 | Phase 1 Clinical | Boehringer Ingelheim Gmbh, Oxford Biotherapeutics Ltd | Small Cell Lung Carcinoma | Details |
| CBA-1535 | CBA-1535 | Phase 1 Clinical | Chiome Bioscience Inc | Carcinoma, Non-Small-Cell Lung; Mesothelioma; Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Triple Negative Breast Neoplasms | Details |
| JANX-008 | EGFR-TRACTr; JANX008; JANX-008 | Phase 1 Clinical | Janux Therapeutics Inc | Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Colorectal Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms | Details |
| QLS-31903 | QLS31903; QLS-31903 | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | Solid tumours | Details |
| CD30 biAb-AATC(The Medical College Of Wisconsin Nonprofit) | Phase 1 Clinical | The Medical College Of Wisconsin Nonprofit | Hodgkin Disease; Leukemia; Lymphoma; Lymphoma, B-Cell; Lymphoma, Large-Cell, Anaplastic; Lymphoma, T-Cell, Cutaneous | Details | |
| QLF-32101 | QLF32101; QLF-32101 | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | Hematologic Neoplasms; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | Details |
| JANX-007 | PSMA-TRACTr; JANX-007 | Phase 1 Clinical | Janux Therapeutics Inc | Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details |
| JNJ-80948543 | JNJ-80948543 | Phase 1 Clinical | Janssen Research & Development Llc | Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Neoplasms | Details |
| PIT-565 | PIT-565 | Phase 1 Clinical | Novartis Pharma Ag | Arthritis, Rheumatoid; Lupus Erythematosus, Systemic; Lymphoma, B-Cell; Neoplasms; Nephrosis; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details |
| CC-312 | CC-312 | Phase 1 Clinical | CytoCares (Shanghai) Inc | Anemia, Hemolytic, Autoimmune; Arthritis, Rheumatoid; Hematologic Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Lupus Erythematosus, Systemic; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Myositis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Purpura, Thrombocytopenic, Idiopathic; Scleroderma, Systemic | Details |
| ASP-2138 | ASP-2138 | Phase 1 Clinical | Astellas Pharma Global Development Inc, Xencor Inc | Carcinoma, Pancreatic Ductal; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Pancreatic Neoplasms; Stomach Neoplasms | Details |
| ISB-2001 | ISB-2001; ABBV-2001 | Phase 1 Clinical | Ichnos Sciences Sa | Multiple Myeloma | Details |
| GR-1901 | GR1901; GR-1901 | Phase 1 Clinical | Chongqing Genrix Biopharmaceutical Co Ltd, Genrix (Shanghai) Biopharmaceutical Co Ltd | Leukemia, Myeloid, Acute | Details |
| QLS-31904 | QLS-31904; QLS31904 | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | Solid tumours | Details |
| RO-7428731 | RO-7428731; RG-6156 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Glioblastoma | Details |
| GBR-1342 | GBR-1342; ISB-1342 | Phase 1 Clinical | Glenmark Pharmaceuticals Ltd | Multiple Myeloma | Details |
| Recombinant humanized anti-CD19/CD3 bispecific antibody(New Time Pharmaceutical) | LNF-1904 | Phase 1 Clinical | Shandong New Time Pharmaceutical Co Ltd | Leukemia, B-Cell; Lymphoma, B-Cell | Details |
| XmAb-968 | XmAb968 | Phase 1 Clinical | Xencor Inc | Hematologic Neoplasms; Leukemia, Promyelocytic, Acute | Details |
| ONC-783 | ONC-783 | Phase 1 Clinical | Oncoc4 Inc | Neoplasms; Solid tumours | Details |
| 1-A-46 | 1A46; 1-A-46; CMG1A46; CMG1A-46; BR110; BR-110; GSK-5926371 | Phase 1 Clinical | Chengdu Chimagen Biosciences Co Ltd, Hisun Biopharmaceutical Co Ltd, Zhejiang BioRay Biopharmaceuticals Co Ltd | Lupus Erythematosus, Systemic; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Neoplasms | Details |
| XmAb-18968 | XmAb-18968 | Phase 1 Clinical | The Medical College Of Wisconsin Nonprofit | Leukemia, Myeloid, Acute | Details |
| SQZ-622(Novartis Pharma) | SQZ-622 | Phase 1 Clinical | Novartis Pharma Ag | Leukemia, Myeloid, Acute | Details |
| Forimtamig | RG-6234 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Multiple Myeloma | Details |
| RG-6232 | RG-6232 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Melanoma | Details |
| RG-6007 | RO-7283420; RG-6007 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Leukemia, Myeloid, Acute | Details |
| SAR-443216 | SAR-443216 | Phase 1 Clinical | Sanofi | Breast Neoplasms; Lung Neoplasms; Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| Recombinant oncolytic type II herpes simplex virus (Binhui Biopharmaceutical) | BS-006; oHSV2-BiTEs; oHSV2CD3-PD-L1 | Phase 1 Clinical | Wuhan Binhui Biotechnology Co Ltd | Melanoma; Neoplasms; Solid tumours; Uterine Cervical Neoplasms | Details |
| JNJ-78306358 | JNJ-78306358; JNJ-6358 | Phase 1 Clinical | Janssen Research & Development Llc | Solid tumours | Details |
| TNB-585 | TNB-585; AMG-340 | Phase 1 Clinical | Teneobio Inc | Prostatic Neoplasms, Castration-Resistant | Details |
| BC-3448 | BC-3448; BC3448 | Phase 1 Clinical | Wuxi BioCity | Solid tumours | Details |
| IBI-389 | IBI-389 | Phase 1 Clinical | Esophageal Neoplasms; Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | Details | |
| RGV-004 | RGV-004 | Phase 1 Clinical | Hangzhou Rongu Biotechnology Co Ltd | Lymphoma, B-Cell | Details |
| NVG-111 | NVG-111 | Phase 1 Clinical | NovalGen Ltd | Carcinoma, Non-Small-Cell Lung; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Melanoma | Details |
| BI-765049 | BI-765049; OBT-624 | Phase 1 Clinical | Oxford Biotherapeutics Ltd | Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| Cizutamig | EMB-06; CND-106; CN106 | Phase 1 Clinical | Shanghai Epimab Biotherapeutics, Inc | Colitis, Ulcerative; Food Hypersensitivity; Graves Ophthalmopathy; Hypersensitivity, Immediate; Lupus Erythematosus, Systemic; Multiple Myeloma; Myasthenia Gravis; Pemphigus; Scleroderma, Systemic | Details |
| GNC-039 | GNC-039 | Phase 1 Clinical | Sichuan Baili Pharmaceutical Co Ltd | Glioma; Hematologic Neoplasms; Neoplasm Metastasis; Solid tumours | Details |
| RO-7425781 | RO-7425781 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Multiple Myeloma | Details |
| RO-7293583 | RO-7293583 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Melanoma; Skin Melanoma; Uveal melanoma | Details |
| Rezetamig | JNJ-8780; JNJ75348780; JNJ-75348780 | Phase 1 Clinical | Teneobio Inc | Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details |
| Y-150(Wuhan Yzy Biopharma/CSPC Pharmaceutical) | Y-150; Y150 | Phase 1 Clinical | CSPC Pharmaceutical Group Ltd, Wuhan Yzy Biopharma Co Ltd | Multiple Myeloma | Details |
| EX-101 | EX-101; EX101 | Phase 1 Clinical | Guangzhou Excelmab Inc | Solid tumours | Details |
| Plamotamab | XmAb-13676 | Phase 1 Clinical | Xencor Inc | Arthritis, Rheumatoid; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Myositis | Details |
| A-337 | A-337 | Phase 1 Clinical | Evive Biotech Ltd | Neoplasms; Solid tumours | Details |
| CCW-702 | CCW-702 | Phase 1 Clinical | Abbvie Inc, The Scripps Research Institute Inc | Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details |
| JCAR-014 | JCAR-014; JCAR021 | Phase 1 Clinical | Fred Hutchinson Cancer Research Center, Juno Therapeutics Inc, Memorial Sloan Kettering Cancer Center, Seattle Children'S Research Institute | Candidiasis; Hodgkin Disease; Leukemia; Leukemia, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Primary mediastinal B cell lymphoma | Details |
| PCART7-CD3 | PCART7-CD3 | Clinical | National University Of Singapore | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Details |
| InHeAb-01 | InHeAb-01; bsAB | Clinical | University Hospital Tuebingen | Neoplasms | Details |
| PMC2129G12 | PMC2129G12 | Forevertech Biotechnologies Co Ltd | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Mouse monoclonal antibody against human CD3 antigen of T lymphocyte (Wuhan Institute of Biological Products) | Approved | Wuhan Institute Of Biological Products Co Ltd | Mainland China | Rejection of organ transplantation | Wuhan Institute Of Biological Products Co Ltd | 1999-01-01 | Rejection of organ transplantation | Details | ||
| Tebentafusp | IMC-gp-100; ImmTAC-gp-100; IMC-gp100 | Approved | Immunocore Ltd | KIMMTRAK | United States | Uveal melanoma | Immunocore Ltd | 2022-01-25 | Melanoma; Skin Melanoma; Uveal melanoma | Details |
| Odronextamab | REGN-1979; ZL-1307 | Approved | Regeneron Pharmaceuticals Inc | ORDSPONO, Ordspono | EU | Lymphoma, Follicular | Regeneron Ireland Designated Activity Company | 2024-08-22 | Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Plasmablastic Lymphoma | Details |
| Teclistamab | JNJ-64007957; JNJ-64007959; JNJ-7957 | Approved | Genmab A/S, Johnson & Johnson Innovative Medicine | TECAYLI, TECVAYLI, 泰立珂 | EU | Multiple Myeloma | Janssen-Cilag International Nv | 2022-08-23 | Hematologic Diseases; Immunoglobulin Light-chain Amyloidosis; Multiple Myeloma; Plasmablastic Lymphoma; Smoldering Multiple Myeloma | Details |
| Teplizumab | PRV-031; MGA-031; hOKT3-gamma-1-ala-ala; hOKT3-γ1-ala-ala | Approved | Tolerance Therapeutics Inc | TZIELD, Teizeild | United States | Diabetes Mellitus, Type 1 | Provention Bio Inc | 2022-11-17 | Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Glucose Intolerance; Hypoglycemia; Psoriasis; Rejection of renal transplantation | Details |
| Linvoseltamab | REGN-5458 | Approved | Regeneron Pharmaceuticals Inc | Lynozyfic | EU | Multiple Myeloma | Regeneron Ireland Designated Activity Company | 2025-04-23 | Food Hypersensitivity; Immunoglobulin Light-chain Amyloidosis; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Renal Insufficiency, Chronic; Smoldering Multiple Myeloma | Details |
| Mosunetuzumab | RG-7828; BTCT-4465A; RO-7030816; CD20-TBD | Approved | Genentech Inc | Lunsumio | EU | Lymphoma, Follicular | Roche Registration Gmbh | 2022-06-03 | Leukemia, Lymphocytic, Chronic, B-Cell; Lupus Erythematosus, Systemic; Lymphoma; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Neoplasms; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Richter's Syndrome | Details |
| Catumaxomab | LP000 | Approved | Neovii Biotech Gmbh, Trion Research | Removab, Korjuny | EU | Ascites | Lindis Biotech GmbH | 2009-04-20 | Ascites; Breast Neoplasms; Carcinoma; Carcinoma, Ovarian Epithelial; Colonic Neoplasms; Neoplasms; Ovarian Neoplasms; Stomach Neoplasms; Urinary Bladder Neoplasms | Details |
| Epcoritamab | GEN-3013; ABBV-GMAB-3013 | Approved | Abbvie Inc, Genmab A/S | Tepkinly, TEPKINLY, EPKINLY | United States | Lymphoma, Large B-Cell, Diffuse | Genmab Us Inc | 2023-05-19 | Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders; Primary mediastinal B cell lymphoma; Richter's Syndrome; Waldenstrom Macroglobulinemia | Details |
| Blinatumomab | BiTE-MT-103; bscCD19xCD3; AMG-103; MT-103; MEDI-538 | Approved | Micromet Inc | Blincyto, 倍利妥 | United States | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Amgen Inc | 2014-12-03 | Burkitt Lymphoma; Leukemia; Leukemia, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Neoplasm, Residual; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Details |
- Overview
- Product List
- Marketed Drug Information
- Clinical Drug Information
Share to: